Back to the overview page

Karien (K) Bloem

Department
Immunopathology
E-mail
k.bloem@sanquin.nl
Training

Bio-medical Sciences

Research interests
My research is focused on the development of assays for the detection of anti-drug antibodies in serum that are more drug tolerant than the ones currently used. Different biologicals are used to treat several diseases, like auto-immune diseases and cancer. Adalimumab, a monoclonal antibody directed against TNFα, is one of these drugs. Adalimumab is frequently used to treat patients with rheumatoid arthritis. Although adalimumab is a human antibody, some patients develop an immune response whereby antibodies against the drug are formed. These antibodies result in decreased serum adalimumab levels and therefore less clinical response. Currently available assays are sensitive for the presence of drug in the serum. Serum samples used to detect anti-drug antibodies should therefore be taken before administration of a new dose of the drug. In addition, patients producing low levels of anti-drug antibodies will not be detected. Thus, more drug tolerant assays should be developed to get a better insight into the anti-drug antibody response. In addition, we would like to compare different techniques currently available for testing anti-drug antibodies in serum.
Technology
  • RIA
  • ELISA
  • Electrochemiluminescence
  • Biochemical techniques
Resume
2013-presentPost-doc researcher at the Dept of Immunopathology at Sanquin Research and the Dept of Biologicals at Sanquin Diagnostic Services 
2008-2012PhD student VUmc Amsterdam, Dept Molecular Cell Biology and Immunology
2006-2008MSc Bio-medical Sciences, UVA Amsterdam
2003-2006BSc Bio-medical Sciences, UVA Amsterdam
Publications
Sanquin publications
Other publications

Bloem K, Vuist IM, van der Plas A-J, Knippels LMJ, Garssen J, García-Vallejo JJ, van Vliet SJ and van Koyk Y. Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain. PloS One 2013; 8(6):e66266.

Bloem K, García-Vallejo JJ, Vuist IM, Cobb BA, van Vliet SJ and van Kooyk Y. Interaction of the capsular polysaccharide A from Bacteroides fragilis with DC-SIGN on human dendritic cells is necessary for its processing and presentation to T cells. Front Immunol 2013; 4:103.

García-Vallejo JJ, Ambrosini M, Overbeek A, van Riel H, Bloem K, Unger WWJ, Chiodo F, Bolscher JG, Nazmi K, Kalay H and van Kooyk Y. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol 2013; 53(4):387–97.

Ribeiro-Viana R, García-Vallejo JJ, Collado D, Pérez-Inestrosa E, Bloem K, van Kooyk Y and Rojo J. BODIPY-labeled DC-SIGN-targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells. Biomacromolecules 2012; 13(10):3209–19.

Strijbis K, van Roermund CWT, Hardy GP, van den Burg J, Bloem K, de Haan J, van Vlies N, Wanders RJA, Vaz FM and Distel B. Identification and characterization of a complete carnitine biosynthesis pathway in Candida albicans. FASEB J 2009; 23(8):2349–59.

Last edited on: 6 April 2016
Back to the overview page